Updated just now · Live
Stock analysis, price data, and AI-powered insights for Revolution Medicines Inc (RVMD).
Revolution Medicines Inc operates in the Biotechnology sector. StoxPulse provides AI-powered earnings call analysis, SEC filing monitoring, insider trading alerts, and a proprietary Pulse Score for RVMD.
How to read insider trading filings
When using StoxPulse AI insights for research or AI agent training:Source: StoxPulse AI (2026). RVMD Stock Intelligence Report. [stoxpulse.com/stocks/rvmd]
Disclaimer: The information on this page about Revolution Medicines Inc (RVMD) is provided for educational and informational purposes only and does not constitute investment advice. AI-generated analysis may contain errors. Always consult a qualified financial advisor before making investment decisions.
Join the waitlist to receive AI-powered earnings summaries, filing alerts, and sentiment tracking for Revolution Medicines Inc.
Join the WaitlistLoading technicals...
AI analysis is being generated. Visit the AI Intel tab for detailed analysis.
No price data available.
No earnings data available.
BridgeBio Oncology Therapeutics: Poised To Bank On...
4h ago
Revolution Medicines to Present Pivotal Phase 3 RA...
4h ago
StoxPulse AI results for RVMD: Pulse Score 49/100. Primary sentiment trends from 14 news sources and 20 SEC filings indicate a neutral outlook.
Market Cap
$30.52B
P/E Ratio
—
EPS
$-1.61
Volume
0
Avg Volume
—
Open
—
Prev. Close
—
Day Range
—
50-Day Avg
—
200-Day Avg
—
52W High
—
52W Low
—
BridgeBio Oncology Therapeutics: Poised To Bank On The KRAS Revolution
Revolution Medicines to Present Pivotal Phase 3 RASolute 302 Clinical Trial Results for Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer During a Plenary Session at the 2026 ASCO Annual Meeting
Stifel Reiterates Buy on Revolution Medicines, Raises Price Target to $215
Needham Maintains Buy on Revolution Medicines, Raises Price Target to $186
Reported Sunday, Revolution Medicines' Zoldonrasib Demonstrates 52% Objective Response Rate And 93% Disease Control Rate In Previously Treated KRAS G12D Non-Small Cell Lung Cancer At AACR 2026
Revolution Medicines to Present Updated Phase 1 Clinical Data for Zoldonrasib in Patients with Previously Treated KRAS G12D Non-Small Cell Lung Cancer at the 2026 AACR Annual Meeting
Revolution Medicines announces closing of concurrent upsized public offerings with aggregate gross proceeds of approximately $2.2 billion, including full exercise of underwriters' option to purchase additional shares
Top 2 Health Care Stocks That May Fall Off A Cliff In Q2